Sanofi-aventis said that Sanofi-aventis US has signed a worldwide research and development agreement with Merck KGaA, Darmstadt, under which Merck's division Merck Serono and Sanofi-aventis US will jointly evaluate novel experimental combinations of agents that could block specific pathways in cancer cells.
The novel combinations involve Merck Serono‘s MEK inhibitor MSC1936369B (also known as AS703026), Sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also known as XL765) and class I PI3K inhibitor SAR245408 (also known as XL147), respectively.
As per the terms of the agreement, each party will be initially responsible for conducting a Phase I dose escalation study of these product candidates.
Sanofi-aventis will be granted a research and development license to MSC1936369B to assess safety and initial clinical activity in combination with its PI3K inhibitor SAR245408.
In conjunction, Merck Serono will be granted a research and development license to SAR245409 in order to assess safety and initial clinical activity in combination with its MEK inhibitor MSC1936369B.
Sanofi-aventis Global Oncology head and senior vice president Debasish Roychowdhury said that this collaboration reinforces their commitment to maximize their portfolio and to provide better treatments for patients with cancer.